Astec Lifesciences Q1 Results FY27: Net Loss of Rs 18 Cr for June 2026 Quarter
- August 3, 2026
- Posted by: Neeraj Pandey
- Category: News
Astec Lifesciences Q1 FY27: Net loss Rs 18 Cr, +43.36% YoY. Revenue Rs 83 Cr, -8.25% YoY. Stock at Rs 650.5 (down 0.74%).
The Astec Lifesciences Q1 results FY27 show consolidated revenue of Rs 83 Cr for the quarter ended 30 June 2026, -8.25% from Rs 91 Cr in Q1 FY26, as Astec Lifesciences reported its numbers on 31 July 2026.
Astec Lifesciences posted a net loss of Rs 18 Cr for the quarter, against a net loss of Rs 33 Cr a year earlier. Shares traded around Rs 650.5 on the NSE, down 0.74% on the day, as investors weighed the print against trends in the pharmaceuticals sector. Here is a full breakdown of the financial highlights, key business factors, dividend status, outlook and risks.
Click Here – Get Free Investment Predictions
Astec Lifesciences Q1 Results FY27 Financial Highlights
The table below summarises Astec Lifesciences’s consolidated numbers for the quarter against the year ago period.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue | Rs 83 Cr | Rs 91 Cr | -8.25% |
| Gross Profit | (Rs 11 Cr) | (Rs 22 Cr) | +47.80% |
| Gross Profit Margin | -13.3% | -24.2% | +10.9 pts |
| Net Profit (PAT) | (Rs 18 Cr) | (Rs 33 Cr) | +43.36% |
| Net Profit Margin | -21.7% | -36.3% | +14.6 pts |
Astec Lifesciences Q1 FY27 Performance Analysis
Revenue moved lower this quarter, down -8.25% year on year to Rs 83 Cr from Rs 91 Cr in the year ago quarter, reflecting softer demand or a high base in the comparable period.
Margins expanded through the June quarter. Gross profit rose +47.80% year on year to a gross loss of Rs 11 Cr (-13.3% margin), a faster clip than the revenue increase, which points to better cost absorption.
The release shows the net loss narrowing. Astec Lifesciences reported a net loss of Rs 18 Cr for the quarter, smaller than a net loss of Rs 33 Cr in Q1 FY26, an improvement of +43.36% even though the company remains loss making.
Check the Univest Screener for Live Data
Astec Lifesciences Q1 FY27: Key Business Factors
1. Revenue Growth Trajectory
Astec Lifesciences reported revenue of Rs 83 Cr for the June 2026 quarter against Rs 91 Cr in the year ago period, a change of -8.25%. This pace of change is a primary swing factor behind the quarter’s numbers, and investors typically track whether it holds up in the following quarters.
2. Gross Margin and Cost Trends
Gross profit moved from a gross loss of Rs 22 Cr in Q1 FY26 to a gross loss of Rs 11 Cr in Q1 FY27, a change of +47.80%. In the pharmaceuticals sector, this line is sensitive to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets, and this quarter’s numbers reflect how Astec Lifesciences managed that balance.
3. Bottom Line and Earnings Quality
The net loss narrowed from a net loss of Rs 33 Cr in Q1 FY26 to a net loss of Rs 18 Cr this quarter, an improvement of +43.36%. The pace of loss reduction is the key number to watch going forward.
Dividend Details
Specific dividend information was not confirmed as part of this results snapshot. Investors should check the official exchange filing on the NSE or BSE website, or track the Univest Screener, for the latest dividend announcement, record date and payment date from Astec Lifesciences.
Astec Lifesciences Outlook for FY27
Management commentary and the underlying trends this quarter will guide how FY27 shapes up for Astec Lifesciences. Investors should track whether the decline in revenue and the narrowing loss in profit continue into the September quarter, along with any updates on capacity, cost or demand that management shares in the coming weeks.
Astec Lifesciences Stock Performance After the Results
Astec Lifesciences shares traded around Rs 650.5 on the NSE, down 0.74% around the time the results were in focus. The 52 week trading range was not confirmed as part of this snapshot; investors can check the live 52 week high and low, along with technical levels, on the Univest Screener before making any trading decision.
Download the Univest iOS App or Univest Android App to track Astec Lifesciences live share price and upcoming quarterly results.
Key Risks
Investors reading through Astec Lifesciences’s numbers should also weigh the following risks.
1. Margin and Input Cost Risk
Being in the pharmaceuticals sector, Astec Lifesciences remains exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal in the trend seen this quarter could pressure margins in coming quarters.
2. Execution and Working Capital Risk
Execution risk around working capital, receivables and order timelines can cause quarter to quarter volatility in reported numbers, so this quarter’s trends should be read over a few quarters rather than in isolation.
3. Macro and Sector Risk
Broader macro factors including interest rates, currency movements and demand cycles in the pharmaceuticals sector could influence how sustainable this quarter’s trends prove to be over FY27.
Conclusion
The Astec Lifesciences Q1 results FY27 show revenue of Rs 83 Cr and a net loss of Rs 18 Cr for the quarter, against Rs 91 Cr and a net loss of Rs 33 Cr in Q1 FY26. A revenue decline and a narrower net loss were the two moving parts this quarter. Investors tracking Astec Lifesciences should watch the next few quarters for confirmation of this trend and consult a SEBI-registered advisor before making investment decisions based on these numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Astec Lifesciences Q1 Results FY27
When were the Astec Lifesciences Q1 results FY27 announced?
Ans. They reflect the quarter ended 30 June 2026, with the data reported as of 31 July 2026. Investors should confirm the exact board meeting date from the official NSE or BSE filing.
What is the PAT in Astec Lifesciences’s Q1 FY27 results?
Ans. The net loss stood at Rs 18 Cr, compared with a net loss of Rs 33 Cr in Q1 FY26, a change of +43.36%.
What was the revenue in Astec Lifesciences’s Q1 FY27 results?
Ans. Revenue came in at Rs 83 Cr for the quarter, a change of -8.25%, compared with Rs 91 Cr in Q1 FY26.
Did Astec Lifesciences declare a dividend with the Q1 FY27 results?
Ans. Dividend details were not confirmed as part of this results snapshot. Check the latest exchange filing on NSE or BSE, or the Univest Screener, for confirmation.
What is the outlook for Astec Lifesciences after Q1 FY27?
Ans. Analysts will track whether the decline in revenue and narrowing loss in profit continue into the September 2026 quarter, along with input cost and demand trends in the pharmaceuticals sector.
How did the stock react to Astec Lifesciences’s Q1 FY27 results?
Ans. Shares traded around Rs 650.5 on the NSE, down 0.74% as the numbers came into focus.
Is Astec Lifesciences a good buy after the Q1 FY27 results?
Ans. The quarter shows a net loss of Rs 18 Cr on revenue of Rs 83 Cr. This article is for educational purposes only and is not investment advice. Consult a SEBI-registered advisor before making any investment decision.
